Priya Rastogi MD
Myeloproliferative Disorder Hematology-Oncology
Assistant Professor, Medicine, University of Pittsburgh School of Medicine
Join to View Full Profile
200 Meyran AveSte 318Pittsburgh, PA 15213
Phone+1 412-383-1650
Fax+1 412-641-1085
Dr. Rastogi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2000 - 2003
Saint Joseph HospitalResidency, Internal Medicine, 1997 - 2000
Wright State University Boonshoft School of MedicineClass of 1997
Certifications & Licensure
PA State Medical License 2003 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Publications & Presentations
PubMed
- Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC).A Fernandez-Martinez, M Tanioka, S G Ahn, P Zagami, T Pascual
Annals of Oncology. 2025-04-01 - CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.Erika P Hamilton, Sibylle Loibl, Thomas Bachelot, Michael Gnant, Naoki Niikura
Future Oncology. 2025-03-01 - 2 citationsLong-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials.Julia Foldi, Neil Carleton, Stewart J Anderson, Priya Rastogi, Adrian Lee
Journal of the National Cancer Institute. 2025-01-01
Press Mentions
Priya Rastogi on Use of the MammaPrint Assay for Predicting Benefit from Extended LetrozoleJanuary 7th, 2025- Gene Assay for MammaPrint May Predict Responses to Extended Letrozole in Low-Risk Breast Cancer SubsetsAugust 30th, 2024
- Advantage of Abemaciclib plus Endocrine Therapy for Early Breast Cancer Endures at 5 YearsJanuary 23rd, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
